- Home
- WWW vs VRDN Comparison
WWW vs VRDN Comparison
Compare WWW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWW | VRDN |
|---|---|---|
| Founded | 1883 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WWW | VRDN |
|---|---|---|
| Price | $19.11 | $20.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $24.44 | ★ $35.46 |
| AVG Volume (30 Days) | 591.4K | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 96.55 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $1,874,300,000.00 | $5,706,000.00 |
| Revenue This Year | $6.65 | $13.73 |
| Revenue Next Year | $5.50 | $279.00 |
| P/E Ratio | $31.64 | ★ N/A |
| Revenue Growth | ★ 6.80 | N/A |
| 52 Week Low | $13.47 | $13.18 |
| 52 Week High | $28.68 | $34.29 |
Technical Indicators
Market Signals| Indicator | WWW | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 36.96 |
| Support Level | $19.10 | $17.97 |
| Resistance Level | $19.63 | $23.40 |
| Average True Range (ATR) | 0.64 | 0.95 |
| MACD | -0.06 | -0.27 |
| Stochastic Oscillator | 20.21 | 8.02 |
Price Performance
Historical ComparisonAbout WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; and Work Group. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear. Geographically, the company operates in United States; Europe, Middle East and Africa; Asia Pacific; Canada; and Latin America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.